Timber Pharmaceuticals Provides Business Update and Announces Second Quarter 2022 Financial Results
11 août 2022 17h20 HE
|
Timber Pharmaceuticals
Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING RIDGE, NJ, Aug. 11, 2022 (GLOBE NEWSWIRE) --...
Timber Pharmaceuticals Receives FDA Breakthrough Therapy Designation for TMB-001 for the Treatment of Congenital Ichthyosis
31 mai 2022 08h00 HE
|
Timber Pharmaceuticals
- Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial - BASKING RIDGE, NJ, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber"...
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
10 sept. 2021 17h58 HE
|
Timber Pharmaceuticals
BASKING RIDGE, NJ, Sept. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study in Congenital Ichthyosis
15 mars 2021 08h30 HE
|
Timber Pharmaceuticals
- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder - Company Awarded Final Tranche of $1.5 Million FDA Orphan Products Clinical Trials...
Timber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
11 sept. 2020 16h29 HE
|
Timber Pharmaceuticals
Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire-- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...
imber Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
11 sept. 2020 16h05 HE
|
Timber Pharmaceuticals
Virtual Presentation on Wednesday, September 16th at 12:30 PM ET WOODCLIFF LAKE, NJ, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”)...